Illinois Public Media News
More and more people are taking advantage of their area state parks for camping, fishing and other recreation. In fact, nearly 2,000,000 people a year pass through two state parks along Route 150. Yet the agency charged with running them has seen significant budget cuts in the past decade. In this installment of our "Life on Route 150" series, Illinois Public Media's Tom Rogers visited the parks and took a snapshot of their health.
(Photo by Tom Rogers/WILL)
(With additional reporting from Illinois Public Radio)
Illinois Gov. Pat Quinn named Chicago schools chief Gery Chico as chairman of the State Board of Education on Tuesday.
Chico's "decades of experience" in education and administration will be a boon to the state's schools, Quinn said at an announcement in Chicago.
Chico became president of the Chicago school board in 1995 when the city took over the schools. He helped close a budget deficit, build new schools and repair old ones, and got credit for raising test scores.
Quinn said in Chicago Tuesday that Chico's "decades of experience'' in education and administration will be a boon to the state's schools.
"I really think it's important to have a leader of distinction, leading our mission of education," Quinn said. "I can't think of anyone better than Gery Chico."
The State Board of Education has less sway over Illinois public schools than a local school board. The state panel is a policymaking body that oversees state and federal grant money and implements education law.
Chico and Quinn said they would focus on a bipartisan reform law that the Legislature sent to the governor this spring and which deals mostly with teachers' rights and qualifications. Quinn also will make early childhood education and helping local governments to build new schools priorities. Chico said he would try to develop board partnerships with other educational organizations such as universities to bring new opportunities to the classroom.
"Teachers and education literally brought us to where we are today," Chico said. "And as the governor said, it is the heart and soul of our state."
Chico lost the Chicago mayor's race this year and finished fifth in the 2004 Democratic Senate primary that Barack Obama won.
Chico replaces Jesse Ruiz, who has served as chairman since September 2004. He was the first chairman appointed under a law signed that month by former Gov. Rod Blagojevich which the governor to name seven new members and the chairman.
The idea was to make the board more accountable to the governor, who months earlier had made an infamous budget speech in which he called the state board "a Soviet-style bureaucracy" in an effort to create an education department that answered to him.
Ruiz retained respect in the Legislature and education communities after the impeached governor's downfall and Quinn praised him Tuesday, saying he chose Chico after looking for someone with similar qualities.
Members of the Illinois State Board of Education receive no salary but are reimbursed for expenses and paid $50 a day when the board meets once a month.
(AP Photo/(M. Spencer Green)
The judge in ousted Illinois Gov. Rod Blagojevich's retrial says he expects the jury to begin deliberating Thursday.
U.S. District Judge James Zagel made the comment shortly after Blagojevich ended his testimony on Tuesday.
Zagel says the defense plans to call two more witnesses Wednesday, when the government could be ready to present its closing arguments.
The judge says jurors could start to deliberate Thursday after the defense finishes their closing.
The testimony stage of the retrial has lasted six weeks.
The government presented a streamlined, three-week case and called 15 witnesses.
The defense called three witnesses over three weeks. Blagojevich was on for most of that time. Chicago Mayor Rahm Emanuel and U.S. Rep. Jesse Jackson Jr. also took the stand for the defense.
Republican voters in the newly redrawn 53rd state Senate District will have a choice in next year's primary election, between Jason Barickman and Shane Cultra. Barickman, who serves in the Illinois House, announced last week he would run for the Senate seat.
Now, State Senator Cultra says he'll run for the office, too, even though he could be facing an expensive primary fight.
"I'm not over confident, but I enjoy my job," Cultra said. "And what I had to do was sit down and look at all the facts, and how my family felt about it. It's quite a commitment, a huge amount of money to raise. I wanted to make sure I had enough funds to be competitive, lined up and committed, before I made that decision."
Cultra was appointed to the state Senate just a few months ago, replacing Dan Rutherford when he became state treasurer. Barickman was chosen to take Cultra's old seat in the House. Cultra said he has more legislative experience than Barickman.
"I have a long history for people to look at," said Cultra, who served eight years in the Illinois House, prior to his appointment to the Senate. "I certainly represent well the district I'm running in. I've lived here all my life."
But Cultra and Barickman will be introducing themselves to a new group of voters in the 53rd Senate District. With its new boundaries, the 53rd District covers all of Iroquois and Ford Counties, most of Livingston County, and parts of Woodford, Vermilion and McLean Counties. It will no longer cover any of Champaign, Tazewell or LaSalle Counties.
Austan Goolsbee, a longtime adviser to President Barack Obama, will resign his post as the chairman of the Council of Economic Advisers this summer to return to teaching at the University of Chicago Graduate School of Business, the White House announced Monday.
Obama called him "one of America's great economic thinkers."
Goolsbee has been the face of the White House on economic news, and is a regular every first Friday of the month explaining the administration's take on the latest jobless numbers.
He brought a mix of levity and a teacher's sensibility to the job, using the White House blog, Facebook or YouTube to illustrate tax cuts, trade, or the auto industry resurgence on a dry-erase board with a dry wit and a gravel voice. He has been at Obama's side for years. He advised Obama during his 2004 Senate race and was senior economic policy adviser during the 2008 presidential campaign and has served on the three-member economic council since the start of the administration.
"Since I first ran for the U.S. Senate, Austan has been a close friend and one of my most trusted advisers," Obama said. "Over the past several years, he has helped steer our country out of the worst economic crisis since the Great Depression, and although there is still much work ahead, his insights and counsel have helped lead us toward an economy that is growing and creating millions of jobs."
Goolsbee took over last September as council chairman, replacing Christina Romer, who left to return to a teaching position at the University of California, Berkley.
He had taught at the University of Chicago for 14 years. His university biography once described him as "insanely committed to his work," noting that Goolsbee was seen in the classroom, wearing a tuxedo, on the day of his wedding.
(AP Photo/Pablo Martinez Monsivais)
Owners of Champaign liquor stores say it's unfair to target one type of business in order to save three positions at the city's police department.
During last night's informational meeting on the suggested 4-percent tax in package liquor sales, those who run stores like Colonial Pantry and Sun Singer say the tax will hurt business, and drive their customers elsewhere.
And Picadilly Beverage Shop owner Jack Troxell claims enacting the tax will force layoffs.
"We're not in a high-margin industry," Troxell said. "We're in a volume industry with low margins. And that's the way it works. If your business drops off, you don't need as many employees. And when that happens, they don't have the same hours, and you can't afford to pay them."
Kam's and Pia's owner Eric Meyer said the liquor tax unfairly singles out an entire sector of business for just one cause. Meyer, who's also the Vice President of the Illinois License Beverage Association, suggests a tax closer to one percent.
The city council tentatively backed the liquor tax last month in order to avoid losing jobs, and ending overnight hours at the police department's front desk. Former Mayors Jerry Schweighart and Dan McCullom criticized the quick manner in which the council proposed the liquor tax. McCullom labeled it 'seat of the pants' decision making without time for deliberating, and Schweighart said when the city council quickly gave the tax their initial support, members abandoned a budget process he'd been working on the council with for months
Mayor Don Gerard, who defeated Schweighart in April's election, said he will consider other revenue proposals, but his intent is saving jobs.
"As the agenda was lined up that night, it was both or neither (the liquor tax and police cuts)," Gerard said. "So we had no choice. Now we can table this until July if we want, and we'll continue to discuss it, but as far as the hullabaloo from the former mayors about the manner in which I do things, well, I just do it a little diffferently, I guess."
The tax is expected to bring in $700,000, well over the $200,000 necessary to restore the police positions. The funds could also go to restore overtime at fire station 4 on Champaign's west side. The liquor tax is the focus of a study session next Tuesday, while business owners suggest different revenue streams, including a hike in the overall sales tax.
The cities of Danville and Decatur have more money to hunt down properties that may have hazardous chemicals sitting underneath them. The land may have once held gas stations, dry cleaners or manufacturers.
Danville will use a $400,000 federal grant announced Monday to investigate past records and eventually test a few of the sites that may pose the most problems to health or redevelopment. Decatur has received an identical grant.
Danville planning and zoning manager Chris Milliken says there may be as many as 300 properties that have some sort of underground contamination. So, he says the city will have to decide which so-called brownfields receive tests. "That includes sites around Danville High School and some other prominent locations," Milliken said. "The main factor engaging the importance of sites we want to pursue is going to be visibility, and then also the potential for redevelopment -- for instance, sites that are along North Vermilion or other developable corridors already."
Milliken expects it will take about a year to identify new sites and conduct testing on about 20 to 40 of them. Danville officials can use those test results to plan cleanups when money becomes available -- those cleanups could range from removing buildings to removing the soil underneath.
(With additional reporting from The Associated Press)
The legal battle to restore funding to Planned Parenthood of Indiana continued in an Indianapolis federal courtroom Monday morning.
Lawyers for Planned Parenthood and the American Civil Liberties Union are seeking an injunction to restore $3 million in federal Medicaid funding.
A recently enacted Indiana law prevents money going to agencies that perform abortion, including Planned Parenthood. The law is the first of its kind in the nation, approved by Indiana Governor Mitch Daniels last month. Daniels contends women in Indiana have other options in seeking medical care other than Planned Parenthood. The law also bans abortions after the twentieth week of pregnancy, unless there is a substantial threat to the woman's life or health.
Planned Parenthood of Indiana says it will close seven of its 28 Indiana health centers if it doesn't get a federal injunction blocking a new state law that cuts off much of its public funding.Indiana.
Betty Cockrum, the president of Planned Parenthood of Indiana, said in an affidavit filed in U.S. District Court in Indianapolis that her organization would close clinics in Bedford, Hammond, Michigan City, New Albany, Terre Haute and two in Indianapolis.
Cockrum said the seven clinics served nearly 21,000 patients last year. Planned Parenthood also would lay off 24 employees. She said $96,000 in donations to keep serving Medicaid patients will run out June 20.
Indiana Attorney General Greg Zoeller said the state shouldn't be locked in a court battle with Planned Parenthood.
"The state's position is that any dispute over Indiana's Medicaid provider qualifications really belong between the federal government and the state of Indiana," Zoeller said following the hearing. "My office stands ready to defend Indiana's statute in the proper forum with the proper party."
U.S. District Judge Tanya Walton Pratt said she will rule on Planned Parenthood's injunction request by the end of the month.
The head of the federal Medicaid program, Donald Berwick, said last week that Indiana's law is illegal and, if it is not changed, the state could face penalties.
Planned Parenthood provides general health care services to 9,300 Medicaid patients in 28 centers around the state.
Rod Blagojevich says Rahm Emanuel raised the issue of having then-Gov. Blagojevich appoint a successor to Emanuel's congressional seat in 2008 when Emanuel became White House chief of staff.
Blagojevich says his staff told him the move would be unconstitutional. Normally, a special election is held for a congressional vacancy.
Blagojevich is testifying for a sixth day at his corruption retrial.
Prosecutor Reid Schar (shahr) introduced the issue of the congressional seat. He asked whether Emanuel had approached Blagojevich about making an appointment. Blagojevich agreed the purpose would be to give the appointee an advantage in a special election.
Blagojevich said he was told by his lawyers and political consultant that such an appointment would be unconstitutional.
A spokesperson for Emanuel, now Chicago's mayor, could not immediately be reached for comment.
They're not cures, but two novel drugs produced unprecedented gains in survival in separate studies of people with melanoma, the deadliest form of skin cancer, doctors reported Sunday.
In one study, an experimental drug showed so much benefit so quickly in people with advanced disease that those getting a comparison drug were allowed to switch after just a few months.
The drug, vemurafenib, targets a gene mutation found in about half of all melanomas. The drug is being developed by Genentech, part of Swiss-based Roche, and Plexxikon Inc., part of the Daiichi Sankyo Group of Japan.
The second study tested Bristol-Myers Squibb Co.'s Yervoy, a just-approved medicine for newly diagnosed melanoma patients, and found it nearly doubled the number who survived at least three years.
"Melanoma has just seen a renaissance of new agents," and more are being tested, said Dr. Allen Lichter, chief executive of the American Society of Clinical Oncology.
The new studies were presented Sunday at the oncology group's annual meeting in Chicago and published online by the New England Journal of Medicine.
"This is really an unprecedented time of celebration for our patients," said Dr. Lynn Schuchter, of the University of Pennsylvania's Abramson Cancer Center. The new drugs are not by themselves cures, but "the future is going to be to build upon the success" by testing combinations of these newer drugs, she said.
Melanoma is on the rise. There were 68,000 new cases and 8,700 deaths from it in the United States last year, the American Cancer Society estimates. Only two drugs had been approved to treat it, with limited effectiveness, until Yervoy, an immune-system therapy, won approval in March.
The experimental drug, vemurafenib, is aimed at a specific gene mutation, making it the first so-called targeted therapy for the disease. The drug got attention when a whopping 70 percent of those with the mutation responded to it in early safety testing.
The new study, led by Dr. Paul Chapman of Memorial Sloan-Kettering Cancer Center in New York, was the key test of its safety and effectiveness. It involved 675 patients around the world with inoperable, advanced melanoma and the gene mutation. They received vemurafenib pills twice a day or infusions every three weeks of the chemotherapy drug dacarbazine.
After six months, 84 percent of people on vemurafenib were alive versus 64 percent of the others.
Less than 10 percent on the drug suffered serious side effects - mostly skin rashes, joint pain, fatigue, diarrhea and hair loss. About 18 percent of patients developed a less serious form of skin cancer. More than a third needed their dose adjusted because of side effects.
The study is continuing, and many remain on the drug, including one of Schuchter's patients: Brian Frantz, a 50-year-old former firefighter from Springfield, Va.
Within a week or two of starting on the drug in September, "we noticed an improvement" and shrinkage in his many tumors, he said. "It was just a miracle."
Schuchter said that's typical of how patients have responded to the drug.
"Within 72 hours, their symptoms improve, pain medicines can be reduced," she said.
The study is a landmark and the results are "very impressive" in people who historically have not fared very well, said Dr. April Salama, a Duke University melanoma specialist.
The study was sponsored by the drug's makers, and many of the researchers consult or work for them. The companies are seeking approval to sell the drug and a companion test for the gene mutation in the U.S. and Europe. A Genentech spokeswoman said the price has not yet been determined.
The other new drug, Yervoy, is not a chemotherapy but a treatment to stimulate the immune system to fight cancer. Dr. Jedd Wolchok of Memorial Sloan-Kettering led the first test of it in newly diagnosed melanoma patients.
About 502 of them received dacarbazine and half also got Yervoy. After one year, 47 percent of those on Yervoy were alive versus 36 percent of the others. At three years, survival was 21 percent with Yervoy versus 12 percent for chemotherapy alone.
Side effects included diarrhea, rash and fatigue. More than half on the new drug had major side effects versus one quarter of those on chemotherapy alone.
Bristol-Myers Squibb paid for the study and many researchers consult or work for the company. Treatment with Yervoy includes four infusions over three months and costs $30,000 per infusion.
New England Journal of Medicine: http://www.nejm.org
Page 631 of 860 pages ‹ First < 629 630 631 632 633 > Last ›